Business Wire

SUNTEC-GROUP

9.12.2021 06:26:14 CET | Business Wire | Pressemeddelelse

Del
SEB, Nordens førende erhvervsbank, vælger SunTecs pakke med løsninger til en koncernomspændende udrulning for at automatisere næste generation af tilbud til fakturering-programmet

SunTec Business Solutions, verdens førende prisfastsættelses- og faktureringsvirksomhed, meddelte i dag, at virksomheden er blevet valgt af Nordens førende erhvervsbank, SEB, til en koncernomspændende global udrulning og til at automatisere deres næste generation af tilbud-til-fakturering-program. SunTecs pakke med løsninger vil digitalisere bankens salgsproces, fra aftalehåndtering og prisfastsættelse til fakturering.

SEB valgte SunTec som teknologipartner til at hjælpe med at opfylde deres vigtigste strategiske initiativer for at blive førende inden for kundeoplevelser, skabe robusthed og fleksibilitet i banken og øge aktiviteterne for store erhvervs- og finansinstitutioner samt SMV'er.

Olle Durelius, Co-Head Transaction Services hos SEB, fortæller, "Vores ambition er at opgradere vores eksisterende processer, og vi er meget glade for at have indgået et partnerskab med SunTec og starter denne rejse for at forbedre og fremme digitalisering og automatisering. Vi var på udkig efter en løsningsudbyder, der kunne understøtte transformationen af vores aktiviteter. I SunTec fandt vi en ligesindet partner, der kunne hjælpe os med at digitalisere vores salgsproces, sikre hurtigere time-to-market, stoppe indtægtslækager, reducere manuel indgriben og sikre, at vi fakturerer klienterne i overensstemmelse med deres forventninger. Med SunTecs pakke med løsninger og platformen Xelerate vil vi understøtte vores aktiviteter inden for likviditetsstyring samt globale depotydelser og "sub-custody" til en start."

Nanda Kumar, grundlægger og CEO hos SunTec, udtaler, "Vi er meget glade for at have indgået et partnerskab med SEB for at styrke deres position som rådgiver til erhvervsklienter, forbedre driftsmæssig fortræffelighed og sikre digital distribution af deres tilbud. Vores robuste pakke med løsninger udrullet på vores Xelerate-platform vil tilbyde en teknologisk infrastruktur, der er API-venlig, modulopbygget af natur, og som automatiserer deres tilbud til fakturering-livscyklus. Denne aftale er en milepæl for os i Norden og viser, at banker i stigende grad skal gå mod en arkitektur i tre lag og udnytte et intelligent midterlag for at sikre agilitet og kundecentrering."

Om SunTec

SunTec er verdens førende prisfastsættelses- og faktureringsvirksomhed, der skaber værdi for virksomheder via cloudbaserede produkter. Mere end 130 klienter i over 45 lande stoler på, at SunTec kan levere meget personligt tilpassede produkter, tilbud, prisfastsættelse, loyalitetsprogrammer og fakturering for mere end 400 millioner slutkunder. SunTecs produkter er baseret på vores cloud-native og cloud-agnostiske, API first, mikrotjenestebaserede proprietære platform, Xelerate, og leveres på stedet, på privat cloud og som SaaS. SunTec har globale aktiviteter, der omfatter USA, Storbritannien, Tyskland, Forenede Arabiske Emirater, Singapore, Canada, Australien og Indien. Besøg www.suntecgroup.com for at få flere oplysninger, eller send en e-mail til os på marketing@suntecgroup.com .

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye